Ipilimumab: a promising immunotherapy for melanoma
- PMID: 21294471
Ipilimumab: a promising immunotherapy for melanoma
Abstract
Antibody-based targeting of the immune suppressor molecule cytotoxic T-lymphocyte antigen 4 (CTLA-4) with ipilimumab has been studied in metastatic melanoma in a number of clinical trials, including a recent phase III trial. This marks the first randomized clinical trial reporting an overall survival benefit using immune modulation in metastatic melanoma. Along with its therapeutic benefits, ipilimumab presents unique challenges to clinicians; these are related to the monitoring of treatment response and the management of drug-related toxicities. This drug is currently being investigated in various cancers, and its indications are likely to be expanded.
Comment in
-
Improving the therapeutic benefits of ipilimumab.Oncology (Williston Park). 2010 Dec;24(14):1288, 1294. Oncology (Williston Park). 2010. PMID: 21294472 No abstract available.
-
Ipilimumab for advanced melanoma: let's not throw caution to the winds.Oncology (Williston Park). 2010 Dec;24(14):1296, 1299. Oncology (Williston Park). 2010. PMID: 21294473 No abstract available.
-
CTLA-4-blocking immunotherapy with ipilimumab for advanced melanoma.Oncology (Williston Park). 2010 Dec;24(14):1302, 1304. Oncology (Williston Park). 2010. PMID: 21294474 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
